Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized trial evaluating low-dose intracoronary adjunctive tenecteplase during primary PCI [percutaneous coronary intervention] for ST-elevation myocardial infarction (ICE-T).

Next Previous
X
Search
Trial Profile

A randomized trial evaluating low-dose intracoronary adjunctive tenecteplase during primary PCI [percutaneous coronary intervention] for ST-elevation myocardial infarction (ICE-T).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenecteplase (Primary)
  • Indications Embolism and thrombosis; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms ICE-T; ICE-T-TIMI49

    • Most Recent Events

    • 20 Nov 2019 Primary endpoint (Percent Diameter Stenosis of the Culprit Lesion Following the First Bolus of Study Drug Prior to Primary Percutaneous Coronary Intervention) has not been met as per results published in the American Journal of Cardiology
    • 20 Nov 2019 Results published in the American Journal of Cardiology
    • 01 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top